GlassScriptPhysician profile
Fernando Moran
NPI 1619321924
$7,016.12
in general payments reported to CMS, 2019-2025
41 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2021: $100 · 2022: $393 · 2023: $2,233 · 2024: $2,138 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,133 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,133.44 |
| Education | $149.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $637.48 | 2023-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $576.97 | 2023-2025 | |
| Novo Nordisk INC | $495.55 | 2023-2025 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $441.78 | 2023-2025 | |
| Ardelyx, INC. | $400.93 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Calliditas Therapeutics US INC. | $346.96 | 2023-2025 | Tarpeyo |
| Amgen INC. | $336.69 | 2023-2025 | Tavneos, Krystexxa |
| Akebia Therapeutics INC | $288.29 | 2023-2025 | Vafseo, Auryxia |
| Insulet Corporation | $257.23 | 2024-2025 | Omnipod, Omnipod |
| Mallinckrodt Hospital Products INC. | $252.22 | 2023-2024 | Terlivaz, Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.33 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $205.59 | 2023-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $190.21 | 2022-2025 | Benlysta |
| Vifor Pharma, INC. | $183.18 | 2023-2025 | Veltassa, Korsuva |
| Inspire Medical Systems, INC. | $178.06 | 2023-2024 | Inspire |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.